exhibit Rh specificity and did not react with nonprimate red cells. When studied by sucrose gradient ultracentrifugation, the vG antibodies to human red cells in these eluates sedimented in the 7S region. It is concluded that in many patients in whom direct antiglobulin tests reveal only cell-bound complement, the complement fixation is mediated in vivo by small quantities of "warmreacting" erythrocyte autoantibodies of the aG class.
INTRODUCTION Red blood cells (RBC) showing positive direct antiglobulin tests with anti-complement serum and negative
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Received for publication 3 October 1969 and in revised form 26 January 1970. reactions with antisera to -yG, yA, or -yM immunoglobulins have been observed in patients with connective tissue disorders, lymphoproliferative diseases, or idiopathic acquired hemolytic disease (1) (2) (3) . The mechanism by which complement is bound to autologous RBC in such cases has been elusive. Earlier attempts to demonstrate autoantibodies in eluates from the RBC of such patients were unsuccessful (4, 5) . Likewise, efforts to detect in these patients' sera complement-fixing autoantibodies reactive with unmodified human red cells have yielded inconsistent or negative results (1, 2). Cold agglutinin titers have usually been normal (1) . Since attachment of complement to RBC can be produced experimentally in vitro by mechanisms other than fixation by antibodies (6) (7) (8) , similar mechanisms may conceivably be operative in clinical illnesses. Alternatively, it seemed possible that small amounts of RBC autoantibodies or antigen-antibody complexes (9) , undetectable by conventional serological techniques, were responsible for complement binding to the RBC of these patients.
To investigate the latter possibilities, a more sensitive method for detection and quantification of -G globulin on the RBC was developed in our laboratory. This new method, a complement-fixing antibody consumption (CFAC) test, can detect as few as 20 molecules of YG per RBC. This test was applied to the study of 16 patients with complement (C')-coated RBC in whom traditional serological studies had failed to indicate the mechanism of this in vivo C' coating.
METHODS

Patients
The clinical diagnoses of the 16 patients studied were: systemic lupus erythematosus (10 patients), idiopathic acquired hemolytic disease (4 patients), lymphosarcoma (1 patient), and rheumatic heart disease (1 patient). Seven patients had mild anemia, but only one patient (H. M.) had an overt hemolytic process at the time of study. Seven patients were receiving corticosteroids. None had recently received blood transfusions. Cold agglutinin titers in all of the patients were 1: 20 or less. Likewise, serum antibodies capable of sensitizing unmodified normal RBC with complement components at 370C could not be detected by indirect antiglobulin tests with anti-complement serum.
Antisera
For all of the complement-fixing antibody consumption (CFAC) tests, a rabbit anti-human -yG globulin serum prepared in our laboratory was used. The specificity of the antiserum was established by immunoelectrophoresis, Ouchterlony analysis, and by complement fixation tests. This antiserum diluted 1: 3000 gave 95% complement fixation with "yG globulin, 65% with F, fragments, and less than 10%o with Fib fragments. This antiserum was diluted 1: 4000 for use in CFAC tests.
The following antisera were used in direct antiglobulin tests: (a) polyvalent rabbit antiserum to whole human serum, (b) a rabbit anti-human -yG globulin serum, and (c) a rabbit antiserum to human complement which had been absorbed with -yG globulin. All RBC samples showing agglutination with the anti-complement serum were further tested with a rabbit antiserum specifically reactive with C'4 (81B) and C'3 (Pic-P#) components of human complement. In all instances, the results with the two anticomplement sera were comparable. In addition, the RBC of 7 of the 16 patients had been tested with rabbit antisera to human -yA and yM globulins, prepared as described elsewhere (10) , and were found to be negative.' All of these antisera had been absorbed thoroughly with human RBC.
Direct antiglobulin tests
RBC from fresh ethylenediaminetetraacetate (EDTA)-blood (see below) were washed three times at room temperature in 20 volumes of isotonic saline. 0.1 ml volumes of 2% washed RBC suspensions and of serial 2-fold dilutions of a given antiglobulin serum were mixed together in tubes. The tubes were immediately centrifuged at 200 g for 1 min and agglutination read macroscopically on a scale of 1+ to 4+.
Complement fixation tests
Complement fixation tests, as used in the CFAC test (see below), applied the method of Wasserman and Levine (11) , with some modifications, to a human -yG: rabbit antihuman -yG system. All dilutions were made in isotonic Veronal buffer containing 0.0005 M MgCl2, 0.00015 M CaCl2, and 0.1%o bovine serum albumin. Guinea pig complement was used in amounts of 1.2-1.8 C'H50 units for each reaction mixture. Antigen (-yG globulin), antibody (anti--yG), and complement were incubated for 18 hr overnight at 4'C. Sheep cells sensitized in a standard fashion with amboceptor (12) were then added, and the reaction mixture incubated at 37'C. When the complement control (complement plus sensitized sheep cells) was approximately 80-90% hemolyzed, the tubes were transferred to an ice bath. The time required for this degree of hemolysis varied with each test ranging from 25 to 35 min. The degree of hemolysis was read by spectrophotometer at 413 mjt. All tests were performed in duplicate using 16 X 100 mm tubes. The total 1 In several hundred direct antiglobulin tests performed in this laboratory on various patients' RBC over the past 7 yr, 84 positive tests have been encountered but none with anti--yA or anti--yM. reaction mixture per tube was 3.5 ml with antigen dilutions composing 0.5 ml, antibody 0.5 ml, guinea pig complement 0.5 ml, sensitized sheep RBC 0.5 ml, and diluent 1.5 ml. Antigen, antibody, and complement controls were run with each test (12) .
Complement-fixing antibody consumption (CFAC) test
This method employs the principle of the antiglobulin consumption test (13) but measures the quantity of unconsumed anti--yG antibody by quantitative complement fixation rather than by hemagglutination titers.
Collection and washing of RBC. Blood from patients or normal subjects was collected in a volume of 1.5% Na2 EDTA and immediately centrifuged at 900 g for 10 min. Plasma, buffy coat, and the upper 0.25 ml of RBC were removed. For the CFAC test, the RBC were washed with isotonic saline, once at room temperature and five times at 4'-5'C. Each washing was carried out with a volume of saline 80 times the packed RBC volume. After the final wash, the RBC were packed by centrifuging at 900 g for 20 min at 4'-5'C. Absorption step. 4 ml of a 1: 4000 dilution of rabbit anti-human -yG globulin serum were added to approximately 1 ml of washed packed human RBC (tube A). The same quantity and dilution of antiserum was also added to a control tube containing no RBC (tube B). The tubes were incubated for 30 min at 4VC with frequent mixing. Tube A was centrifuged at 900 g for 20 min and the supernatant was removed.
Complement fixation step. The amount of anti--yG antibody remaining in the supernatants from tubes A and B was determined as follows. To 0.5 ml of each supernatant, 0.5 ml of guinea pig complement (1.2-1.8 C'Hw units) and 0.5 ml of human -yG globulin (0.02 jig N/ml) was added.
The complement fixation test as described above was then carried out. The concentration of human yG globulin used in the complement fixation test was that which had been shown to be slightly in antigen excess in the standard complement fixation analysis with 1: 4000 rabbit anti--yG serum. This was 0.02 ;&g N/ml of -yG globulin, and it gave 60-90% complement fixation in repeated tests.
Controls included those for any slight nonspecific hemolysis contributed by the human RBC, as well as that from the sensitized sheep RBC; the combined values from these two sources were used as the zero blank for reading the experimental tubes. The extent of these combined hemolysis values was generally less than 10% of the total hemolysis in the system.
Quantification. The results of the antibody consumption test were expressed as a reduction of per cent complement fixation. This was calculated by subtracting the per. cent complement fixation observed with rabbit anti--yG serum absorbed with human RBC (tube A) from that observed with the unabsorbed rabbit anti--yG serum (tube B). For example, if the complement fixation observed with the RBC-absorbed anti--yG serum was 40% and that observed with the unabsorbed anti-yG serum was 90%o, the reduction of per cent complement fixation would be 50. When the reduction of per cent complement fixation was complete, the test was repeated with fewer RBC to provide a point on the standard curve (Fig. 1) .
The standard curve relating reduction of complement fixation to quantity of -yG globulin bound to RBC was prepared with group A, RBC coated with known amounts of yG anti-A antibody. To obtain -yG anti-A, a normal subject of blood group A was hyperimmunized with A substance (14) , resulting in a 1:512 titer of anti-A as measured by indirect antiglobulin test. -yG globulin was separated from this serum on a diethylaminoethyl (DEAE)-cellulose column using 0.01 M phosphate buffer, pH 8.0. The eluted yG globulin fraction was concentrated by negative pressure dialysis through a colloidon membrane from a volume of 180 ml to 18 ml, and then shown to have no other immunoglobulins in it by Ouchterlony analysis. Precipitin analysis (15) of this preparation with soluble A substance 2 revealed the concentration of anti-A to be 28.6 ,ug N/ml. Group A RBC were incubated at 37°C for 1 hr and at 4°C overnight with quantities of the -yG anti-A preparation adjusted to contain 50, 100, 200, 400, 800, and 1600 molecules of -yG anti-A antibody per RBC respectively. The supernatants recovered from each of these mixtures were concentrated 30-to 50-fold by negative pressure dialysis through collodion membranes. Residual anti-A could not be demonstrated by saline agglutination or indirect antiglobulin tests in any of the supernatants. From this, the assumption can 2 Pfizer Diagnostics, New York.
be made that more than 90% of the yG anti-A in each mixture had been bound to the RBC, giving a corresponding limit to the possible error in constructing the standard curve. The RBC were sufficiently sensitized to give the macroscopic antiglobulin reactions shown in Table I . Complement-fixing antibody consumption (CFAC) tests were performed with the RBC from each of the variously sensitized preparations described above. A straight line relationship was found between reduction of per cent complement fixation (C'F) and the log of the quantity of human yG globulin calculated to be present on the absorbing RBC (Fig. 1 ). This curve was not affected by the intensity of the -yG globulin sensitization per RBC through the ranges tested (50-1600 molecules per RBC), i.e., the absorption of anti-yG globulin as shown by reduction of C'F was responsive to the total cell-bound yG globulin.
For measuring the yG globulins on an unknown RBC sample, the reduction of per cent C'F was obtained using a measured number of RBC. By reference to the standard curve, the reduction in per cent C'F was obtained using a measured number of the RBC. By reference to the standard curve, the reduction in per cent C'F can then be expressed as ,ug yG globulin per RBC or as molecules of 'yG per RBC. The calculation of the number of yG molecules in all of such experiments has been based on a molecular weight of 160,000 for human yG globulin. RBC counts were done microscopically on a standard hemocytometer. In experiments for preparation of the standard curve, the average of eight separate counts was used. All other RBC counts were based on the average of two separate determinations.
Preparation of RBC eluates
The method of Kochwa and Rosenfield (16) was followed with some minor modifications. Eluates were prepared from 100-250 ml of the patient's blood collected in 1.5% EDTA (nine parts blood to one part EDTA). These volumes of whole blood represented packed RBC volumes from 40 ml to 120 ml. The RBC were thoroughly washed with 20 volumes of isotonic saline, once at room temperature and five times at 40-50C, and then were made up to a 10% suspension in saline. For preparing RBC stromata, the RBC were lysed by adding 0.5 ml of a 0.5% solution of digitonin for each 10 ml of the 10% RBC suspension. RBC stromata were washed five times with large volumes of cold isotonic saline (4°-5°C). 0.1 M glycine buffer pH 3 was added to the RBC Sucrose density gradient ultracentrifugation
The sedimentation behavior of the antibodies in the eluates was determined by sucrose density gradient centrifugation using catalase (11S) and aldolase (8S) markers (17) . The gradient was continuous, ranging from 10 to 40%o sucrose in 0.15 saline and had a volume of 4.1 ml.
The samples were centrifuged at 35,000 rpm for 18 hr at 4VC in a Spinco model L ultracentrifuge using an SW 50 rotor. The gradient was then divided by puncture from below into 32 fractions consisting of 10 drops each. Indirect antiglobulin tests with anti-'yG serum were performed on the respective fractions. To investigate the possibility that our estimates of RBC-bound aG globulin were due to loss of rabbit antihuman aG activity by dilution with solute trapped in the packed RBC, 10 ul of 'I-labeled human serum albumin were added to the anti-human 'YG serum. The loss of radioactivity in this antiserum after absorption with RBC was measured. It was determined that the amount of solute trapped in 1 ml of packed RBC was 0.1 ml or less, and that the actual effective dilution of our standard (1: 4000) rabbit anti-yG globulin was, at most, 1: 4100. This highest possible dilution of the standard anti-yG was not sufficient to induce a detectable change in per cent of C'F when the standard amount of yG globulin (0.02 Mg N) was added.
RESULTS
Comparison
Nonspecific adsorption of rabbit anti-human^jG to human RBC appeared to be a most unlikely explanation of our data. CFAC tests were performed with another antigen-antibody system standardized in a fashion similar to the anti-yG: aG globulin system described above.
Rabbit anti-egg albumin "absorbed" with 1 ml of packed human RBC gave no reduction of C'F with a standard quantity of egg albumin as antigen. In addition, 1.5 ml (5.3 X 1010) of packed goat RBC did not produce any significant reduction of the ability of our standard antihuman -vG serum to fix complement with the standard amount of human aG as antigen.
Since it was not possible to prepare packed RBC entirely free of white blood cells (WBC) and platelets, the possibility was considered that the WBC or platelets could have a sufficiently heavy coating of yG globulins to account for reduction of per cent C'F in our tests. To investigate this, CFAC tests were initially attempted on isolated WBC preparations. The anticomplementarity which resulted made results uninterpretable. The following method was found to circumvent this problem. (Table II) . The numbers of YG molecules per RBC were significantly greater than those found on the RBC from 23 normal subjects all of whom showed less than 35 molecules of 'vG per RBC (Table II) . The RBC of three patients with C'-coated RBC (R. B., P. F., and J. M.) had numbers Table II whose RBC had shown (a) positive direct antiglobulin reactions with anti-complement serum, (b) negative direct antiglobulin reactions with anti--yG serum, and (c) increased numbers of RBC-bound -rG globulin by the CFAC test. All seven of these eluates, when incubated with normal human RBC at 37°C for 1 hr, were able to sensitize these RBC with 'G globulin so that they gave a positive antiglobulin reaction with anti-yG serum (Table III ). Five eluates so tested gave negative indirect antiglobulin reactions with an anti-,vM serum. Eluates prepared from comparable or greater numbers of RBC from eight normal subjects, when similarly tested, gave negative results.
The specificities of five of these RBC eluates were tested (Table IV) . All five failed to sensitize detectably either sheep or rabbit RBC. Two of three eluates reacted positively with rhesus monkey RBC (Table IV) . Three eluates were able to sensitize human Rh.51i RBC to the same degree as human R2R2 RBC, indicating a "non-Rh" specificity of the antibodies in these eluates. Inadequate amounts of eluate in the other four patients precluded testing with Rh..ii RBC. The RBC eluates from six patients were tested for their abilities to fix human complement to normal RBC, as determined by the agglutinability of such cells by specific anti-C' serum. As shown in Table V , when five of the six eluates were incubated with human RBC in the absence of a C' source (heated serum), the test RBC nonetheless acquired some reactivity with the anti-C' serum. This phenomenon has been encountered in other studies (18, 19) and can be attributed to antibody-complement complexes in eluates derived entirely from the patients' RBC.' On the other hand, when fresh normal human serum was provided as a source of new C' during the in vitro incubation, the subsequent reactions of the test RBC with anti-C' serum were distinctly and reproducibly stronger in every case but one (Table V) . This augmentation is taken to mean active fixation of C' components to the RBC surface, over and above that which was carried over passively in complex with autoantibody. In similar experiments, RBC eluates from two normal subjects did not fix complement to normal RBC after incubation in either fresh or heat-inactivated serum.
Sucrose gradient ultracentrifugation was performed on three eluates (H. M., I. R., and R. G.). The results of the run on eluate I. R. are shown in Fig. 3 (Table III) , (b) the specificity of these reactions for human RBC (Table IV) , and (c) their ability to fix complement (C') to unmodified human RBC at 37°C (Table V) (24) .
Efforts by others to demonstrate C'-fixing red cell antibodies in eluates from C'-coated red cells have heretofore been unsuccessful (4, 5) . The most likely explanation for these previous failures is that elution was made from an insufficient number of red cells and that the eluate was insufficiently concentrated. In our patients, RBC (25) . Furthermore, the capacity of the RBC eluates to fix human complement to normal RBC is a known characteristic of many RBC autoantibodies. The finding that the autoantibodies in the eluates reacted with Rh..ii RBC is also consistent with the observation that complement-fixing RBC autoantibodies usually do not show specificity for Rh antigens (26, 2) .
The present observations are in keeping with earlier studies on human RBC apparently coated with complement alone. Gilliland and Turner (27) had found that when the C'-coated RBC of certain rheumatoid arthritis patients were incubated at 370C with normal RBC in the presence of fresh normal serum, the normal RBC acquired C' on their surfaces. However, when incubation of the RBC was performed in complement-inactivated serum or in saline, the normal RBC did not acquire complement components. These results suggested that during in vitro incubation of the patient's complement-coated RBC with normal RBC in the presence of fresh normal serum, small quantities of antibody transferred from the patient's RBC to the normal RBC, resulting in fixation of C' on the normal RBC surface.
Jenkins and Eyster (19) reported that eluates prepared by acid elution from RBC stromata of C'-coated RBC fixed complement to normal RBC. Although they were unable to demonstrate immunoglobulins on such cells or in these eluates, they showed that the property of these eluates to fix complement to normal RBC resided in the YG area obtained from Sephadex G-200 chromatography.' (34, 35) , this seems less likely for hemolytic disease of the "warm-type," in which free serum antibody is usually absent or difficult to demonstrate.
In conclusion, from these observations an entirely reasonable explanation can be offered for the previously unexplained occurrence of C'-coated RBC in many patients with connective tissue disorders, lymphoproliferative diseases, and idiopathic acquired hemolytic disease: a low concentration of "warm-reacting" aG autoantibody with highly efficient C'-fixing activity. Our failure to detect cell-bound -yG antibody in 3 of the 16 cases studied could be due to either the dissociation of low affinity antibody (see above), the presence of antibody belonging to another immunoglobulin class (36, 37) , or the operation of other mechanisms in some patients.
